Skip to main content
Premium Trial:

Request an Annual Quote

Minerva Licenses Osmetech's SAM Tech to Study Functional Proteomics

NEW YORK (GenomeWeb News) — Minerva Biotechnologies has non-exclusively licensed Osmetech’s self-assembling monolayer technology for use with its proprietary nanoparticle technology, Osmetech said today.
Osmetech said Minerva will use the SAM technology to study signal enhancement, drug design, drug screening, and functional proteomics.
Osmetech exclusively licensed the technology from Harvard University a decade ago. The IP was invented in part by Minerva founder and CSO Cynthia Bamdad.
SAM technology is used in biosensing to minimize background signal, provide for uniform functionalized attachment of molecules to surfaces, and reduce nonspecific aggregation events. 
Osmetech uses the technology with nucleic acid analyte diagnostics. For instance, late last year the company licensed the technology to Ohmx, which planned to use it in non-nucleic acid analyte detection schemes.
Osmetech is “currently in dialog” with an undisclosed number of other companies that have expressed interest, Edward Kreusser, Osmetech’s vice president of intellectual property and legal affairs, said in a statement.  
Financial terms of the agreement were not released.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.